These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. Increased clearance of low density lipoprotein precursors in patients with heterozygous familial defective apolipoprotein B-100: a stable isotope approach. Pietzsch J; Wiedemann B; Julius U; Nitzsche S; Gehrisch S; Bergmann S; Leonhardt W; Jaross W; Hanefeld M J Lipid Res; 1996 Oct; 37(10):2074-87. PubMed ID: 8906585 [TBL] [Abstract][Full Text] [Related]
47. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. Ginsberg HN; Le NA; Goldberg IJ; Gibson JC; Rubinstein A; Wang-Iverson P; Norum R; Brown WV J Clin Invest; 1986 Nov; 78(5):1287-95. PubMed ID: 3095375 [TBL] [Abstract][Full Text] [Related]
48. Effect of n-3 fatty acids on metabolism of apoB100-containing lipoprotein in type 2 diabetic subjects. Ouguerram K; Maugeais C; Gardette J; Magot T; Krempf M Br J Nutr; 2006 Jul; 96(1):100-6. PubMed ID: 16869997 [TBL] [Abstract][Full Text] [Related]
49. Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes: a stable isotope kinetic study. Duvillard L; Pont F; Florentin E; Galland-Jos C; Gambert P; Vergès B Eur J Clin Invest; 2000 Aug; 30(8):685-94. PubMed ID: 10964160 [TBL] [Abstract][Full Text] [Related]
50. Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates. Forster LF; Stewart G; Bedford D; Stewart JP; Rogers E; Shepherd J; Packard CJ; Caslake MJ Atherosclerosis; 2002 Sep; 164(1):129-45. PubMed ID: 12119202 [TBL] [Abstract][Full Text] [Related]
51. Postprandial triglyceride-rich lipoprotein metabolism and insulin sensitivity in nonalcoholic steatohepatitis patients. Cassader M; Gambino R; Musso G; Depetris N; Mecca F; Cavallo-Perin P; Pacini G; Rizzetto M; Pagano G Lipids; 2001 Oct; 36(10):1117-24. PubMed ID: 11768156 [TBL] [Abstract][Full Text] [Related]
52. Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia. Chan DC; Watts GF; Barrett PH; Beilin LJ; Redgrave TG; Mori TA Diabetes; 2002 Aug; 51(8):2377-86. PubMed ID: 12145148 [TBL] [Abstract][Full Text] [Related]
53. Effects of short- and long-term growth hormone replacement on lipoprotein composition and on very-low-density lipoprotein and low-density lipoprotein apolipoprotein B100 kinetics in growth hormone-deficient hypopituitary subjects. Kearney T; de Gallegos CN; Proudler A; Parker K; Anayaoku V; Bannister P; Venkatesan S; Johnston DG Metabolism; 2003 Jan; 52(1):50-9. PubMed ID: 12524662 [TBL] [Abstract][Full Text] [Related]
54. Contribution of intestinal triglyceride-rich lipoproteins to residual atherosclerotic cardiovascular disease risk in individuals with type 2 diabetes on statin therapy. Taskinen MR; Matikainen N; Björnson E; Söderlund S; Inkeri J; Hakkarainen A; Parviainen H; Sihlbom C; Thorsell A; Andersson L; Adiels M; Packard CJ; Borén J Diabetologia; 2023 Dec; 66(12):2307-2319. PubMed ID: 37775612 [TBL] [Abstract][Full Text] [Related]
55. Changes in apolipoprotein B100-containing lipoprotein metabolism due to an estrogen plus progestin oral contraceptive: a stable isotope kinetic study. Duvillard L; Dautin G; Florentin E; Petit JM; Gambert P; Vergès B J Clin Endocrinol Metab; 2010 May; 95(5):2140-6. PubMed ID: 20200333 [TBL] [Abstract][Full Text] [Related]
56. Low-density lipoprotein particle size, triglyceride-rich lipoproteins, and glucose tolerance in non-diabetic men with essential hypertension. Rubies-Prat J; Ordóñez-Llanos J; Martin S; Blanco-Vaca F; Molina L; Goday A; Pedro-Botet J Clin Exp Hypertens; 2001 Aug; 23(6):489-500. PubMed ID: 11478431 [TBL] [Abstract][Full Text] [Related]
57. In treatment-naïve and antiretroviral-treated subjects with HIV, reduced plasma adiponectin is associated with a reduced fractional clearance rate of VLDL, IDL and LDL apolipoprotein B-100. Das S; Shahmanesh M; Stolinski M; Shojaee-Moradie F; Jefferson W; Jackson NC; Cobbold M; Nightingale P; Umpleby AM Diabetologia; 2006 Mar; 49(3):538-42. PubMed ID: 16432707 [TBL] [Abstract][Full Text] [Related]
58. Apolipoprotein E kinetics: influence of insulin resistance and type 2 diabetes. Bach-Ngohou K; Ouguerram K; Nazih H; Maugère P; Ripolles-Piquer B; Zaïr Y; Frénais R; Krempf M; Bard JM Int J Obes Relat Metab Disord; 2002 Nov; 26(11):1451-8. PubMed ID: 12439646 [TBL] [Abstract][Full Text] [Related]
59. Effects of insulin and acipimox on VLDL1 and VLDL2 apolipoprotein B production in normal subjects. Malmström R; Packard CJ; Caslake M; Bedford D; Stewart P; Yki-Järvinen H; Shepherd J; Taskinen MR Diabetes; 1998 May; 47(5):779-87. PubMed ID: 9588450 [TBL] [Abstract][Full Text] [Related]
60. Hyperapobetalipoproteinemia with compositional abnormality of LDL and IDL, a characteristic lipoprotein alteration in essential hypertension. Ryomoto KI; Suzuki M; Kanazawa A; Hasegawa M; Kimura Y; Yamamura T; Harano Y Am J Hypertens; 2000 Jun; 13(6 Pt 1):617-24. PubMed ID: 10912744 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]